Skip to main content
NIH funding notice PA-16-181

Development and Commercialization of Technologies to Create, Characterize or Improve Animal Models of Human Disease (R41/R42)

Closed on September 5, 2019.

Posted
April 11, 2016
Close date
September 5, 2019
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $450,606 in first-year total cost, median $225,303.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1 IMST-H (15)]2

Most frequent institutions

  1. ATGC, INC.1
  2. B-MOGEN BIOTECHNOLOGIES, INC.1
Competing awards under PA-16-181 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2018Development of mitochondrial disease mouse models1R41OD026567-01KOOB, MICHAEL DOTTO, NEILB-MOGEN BIOTECHNOLOGIES, INC., MN$224,856ZRG1
2017Ground state rabbit pluripotent stem cells1R41OD023245-01A1YING, QILONGATGC, INC., MI$225,750ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PA-16-181: Development and Commercialization of Technologies to Create, Characterize or Improve Animal Models of Human Disease (R41/R42) | ScienceDex | ConductScience